Suchergebnisse - "Bylicki, Olivier"

PubPharm (6)

1

Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies : A multicentre phase II open-label non-randomised study GFPC 06-2018

enthalten in: European journal of cancer (Oxford, England : 1990) | 2023

von Bylicki, O. | Tomasini, P. | Radj, G. | +20

2

First-Line Treatment of Advanced Non-Small-Cell Lung Cancer with Immune-Checkpoint Inhibitors : New Combinations and Long-Term Data

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2022

von Boussageon, M. | Swalduz, A. | Chouaïd, C. | +1

ErratumIn: BioDrugs. 2023 Jan;37(1):121. - PMID 36401075

3

ROS-1 Fusions in Non-Small-Cell Lung Cancer : Evidence to Date

enthalten in: Current oncology (Toronto, Ont.) | 2022

von Gendarme, S. | Bylicki, O. | Chouaid, C. | +1

4

Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation : GFPC 01-2018

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Guisier, F. | Dubos-Arvis, C. | Viñas, F. | +15

CommentIn: J Thorac Oncol. 2020 Apr;15(4):489-492. - PMID 32216943

5

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma

enthalten in: Medicine | 2020

von Bylicki, O. | Guisier, F. | Monnet, I. | +8

6

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

enthalten in: Targeted oncology | 2017

von Bylicki, O. | Paleiron, N. | Margery, J. | +6

1
[1]